Last reviewed · How we verify
Avodart
At a glance
| Generic name | Avodart |
|---|---|
| Also known as | Avodart/placebo, dutasteride, Dutasteride |
| Sponsor | GlaxoSmithKline |
| Target | 3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Benign prostatic hyperplasia
Common side effects
- Impotence
- Decreased libido
- Ejaculation disorders
- Breast disorders
Serious adverse events
- High-grade prostate cancer (Gleason score 8-10)
Key clinical trials
- Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects (PHASE1)
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Dutasteride in Patients With Low-grade Non-muscle Invasive Bladder Cancer (PHASE2)
- Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP
- Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression (NA)
- Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia (PHASE1)
- Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |